AAA announced that quality of life findings from the pivotal NETTER-1 Phase III study investigating the treatment of Lutetium Lu 177 Dotatate in patients with somatostatin receptor positive midgut neuroendocrine tumors (midgut NETs) was presented at the 14th Annual Conference of the European Neuroendocrine Tumor Society (ENETS), March 8-10 in Barcelona, Spain.
The details of the presentations are as follows:
Abstract # 1676: NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumours
Session Date: March 9, 2017
To read more please visit the AAA website or read the full press release here.
Recent News
Modernising Support for Independent Living: The Health and Disability Green Paper
In April this year, the government published a Green paper consultation on proposals for PIP reform. The paper was introduced by The Rt Hon Mel Stride MP in April 2024: Former Secretary of State for Work and Pensions: “We want to ensure that we have a welfare system...
PERT Update: Addressing Current Shortages
At Neuroendocrine Cancer UK, we have been actively collaborating with our charity partners to tackle the urgent need to resolve the ongoing shortages of Pancreatic Enzyme Replacement Therapy (PERT). Our joint efforts have resulted in significant strides towards...
June Highlights
Thanks to you, this is what we have been able to achieve this month. - - 🎉 June Highlights! 🎉 💊 We've been working...